title: Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.
authors.forename: B
authors.initials: B
authors.lastname: Jönsson
authors.forename: O
authors.initials: O
authors.lastname: Ström
authors.forename: J A
authors.initials: JA
authors.lastname: Eisman
authors.forename: A
authors.initials: A
authors.lastname: Papaioannou
authors.forename: E S
authors.initials: ES
authors.lastname: Siris
authors.forename: A
authors.initials: A
authors.lastname: Tosteson
authors.forename: J A
authors.initials: JA
authors.lastname: Kanis
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics*; D050071:Bone Density Conservation Agents / Q000191:economics*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000191:economics*; D058866:Osteoporotic Fractures / Q000191:economics*; D053245:RANK Ligand / Q000191:economics*
chemical_list: D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents; D053245:RANK Ligand
references.citation: Osteoporos Int. 2011 Mar;22(3):967-82
references.pmid: 20936401